Novartis applies to the Court of Appeal following the recent judicial review on a Clinical Commissioning Group (CCG) policy related to the routine use of an unlicensed medicine on the NHS
Nov 01, 2018
Novartis previously announced its intention to appeal the recent judicial review judgment on a CCG policy related to the routine use of an unlicensed medicine for the treatment of wet age-related macular degeneration on the NHS. The first step in launching an appeal of a High Court decision is to seek permission from the High Court itself. In this instance, as in most cases, the High Court has not granted permission to challenge its decision so Novartis is now seeking permission from the Court of Appeal, the next step in the process.
The High Court judgment challenges the statutory role of the MHRA (Medicines and Healthcare products Regulatory Agency) and EMA (European Medicines Agency) in protecting public health and assuring the quality of medicines. It puts the financial burden faced by the NHS bodies above a patient’s right to medicines which have met the MHRA and EMA regulatory requirements for efficacy, safety and quality, as well as NICE cost-effectiveness hurdles, and the UK public are now being asked to accept this.We believe this sets a dangerous precedent and must be challenged.
Novartis is expecting a decision on whether permission to appeal will be granted by the Court of Appeal by the end of the year.
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 125,000 full-time-equivalent
associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.
In the UK, we employ approximately 1,500 people to serve healthcare needs across the whole of the UK, as well as supporting the global operations of Novartis. In 2017 Novartis invested almost £30million in R&D and is a leading sponsor of clinical trials in the UK. For more information, please visit www.novartis.co.uk.